Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in its own shares conducted on April 15, 2026, and filed on April 16, 2026. The transaction was executed by BNP Paribas SA as part of GSK's existing share buyback programme, which was announced on February 17, 2026, under a non-discretionary agreement.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase event rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this document).
- Shares Purchased: 325,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,142.00 GBp; highest price paid was 2,201.00 GBp.
- Average Price: Volume-weighted average price paid was 2,179.65 GBp.
- Trading Venues: Purchases were made on BATE (58,098 shares), CHIX (63,460 shares), and XLON (203,442 shares).
- Programme Progress: Since February 17, 2026, GSK has purchased a total of 19,196,521 ordinary shares.
Material Changes and Capital Structure
Following the April 15 purchase, GSK's capital structure was updated as follows:
- Treasury Shares: The company now holds 259,087,615 ordinary shares in treasury.
- Shares in Issue: There are 4,057,103,154 ordinary shares in issue (excluding treasury shares).
- Voting Rights: The total number of voting rights is 4,057,103,154.
- Treasury Voting Percentage: The percentage of voting rights attributable to treasury shares is 6.39%.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.
Investor Verification Checklist
- Verify the total number of treasury shares held (259,087,615) against the company's latest capitalization table.
- Confirm the 6.39% voting rights threshold for treasury shares to assess potential dilution or control implications.
- Review the remaining capacity of the buyback programme announced on February 17, 2026, to understand future capital allocation plans.
- Check the volume-weighted average price (2,179.65 GBp) against the prevailing market price on April 15, 2026, to evaluate execution efficiency.